

Harry La Janssen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10611016/publications.pdf>

Version: 2024-02-01

155
papers

20,619
citations

17405

63
h-index

10127

140
g-index

156
all docs

156
docs citations

156
times ranked

16989
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1766-1775.	2.4	24
2	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	2.4	9
3	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	1.8	48
4	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
5	Getting to HBV cure: The promising paths forward. <i>Hepatology</i> , 2022, 76, 233-250.	3.6	70
6	Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. <i>Hepatology</i> , 2022, 76, 303-316.	3.6	6
7	Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. <i>Hepatology Communications</i> , 2022, 6, 935-949.	2.0	15
8	Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2022, 227, 113-122.	1.9	8
9	Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time. <i>Hepatology</i> , 2021, 73, 2141-2154.	3.6	11
10	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1933-1940.e1.	2.4	14
11	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	2.4	27
12	Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 463-472.	2.4	64
13	Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults. <i>Hepatology</i> , 2021, 73, 968-982.	3.6	43
14	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. <i>Hepatology</i> , 2021, 73, 1652-1670.	3.6	9
15	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	3.6	23
16	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651.	3.6	11
17	Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 942-950.	1.0	16
18	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	2.6	5

#	ARTICLE	IF	CITATIONS
19	Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. <i>Hepatology</i> , 2021, 74, 2395-2409.	3.6	36
20	Mean HBsAg decline at week 24 of PEGIFN α -based treatment predicts subsequent rate of HBsAg clearance suggesting a valuable endpoint for early development HBV trials. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1563-1569.	1.0	11
21	IDDF2021-ABS-0078...Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD). , 2021, , .		0
22	Controversies in Treating Chronic Hepatitis B Virus Infection. <i>Clinics in Liver Disease</i> , 2021, 25, 805-816.	1.0	0
23	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
24	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
25	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
26	Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2020, 158, 1185-1190.	0.6	18
27	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
28	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	1.8	69
29	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
30	Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2020, 4, 1332-1345.	2.0	28
31	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	1.8	75
32	Hepatitis B Core-Related Antigen Levels Predict Pegylated Interferon- α Therapy Response in HBeAg-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2020, 25, 217-222.	0.6	6
33	Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 69, 2338-2348.	3.6	37
34	Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. <i>Gut</i> , 2019, 68, 1088-1098.	6.1	97
35	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	1.9	66
36	HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection. <i>JHEP Reports</i> , 2019, 1, 170-178.	2.6	20

#	ARTICLE	IF	CITATIONS
37	Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019, 39, 1837-1844.	1.9	18
38	Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019, 157, 227-241.e7.	0.6	99
39	Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1840-1849.e16.	2.4	82
40	Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 182-191.e1.	2.4	53
41	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. <i>Hepatology</i> , 2018, 68, 839-847.	3.6	72
42	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	1.8	291
43	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	1.8	88
44	Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1641-1649.e6.	2.4	29
45	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 68, 431-440.	1.8	147
46	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
47	Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 967-977.	1.8	21
48	Microarray Expression Profiling of microRNAs Reveals Potential Biomarkers for Hepatocellular Carcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2018, 245, 89-98.	0.5	39
49	Treatment of Hepatitis B. , 2018, , 485-500.e5.		0
50	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 67, 370-398.	1.8	3,803
51	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	3.6	239
52	Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. <i>Journal of Hepatology</i> , 2017, 67, 339-348.	1.8	56
53	How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. <i>Journal of Hepatology</i> , 2017, 67, 1281-1297.	1.8	132
54	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	1.8	225

#	ARTICLE	IF	CITATIONS
55	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	1.8	267
56	Reply. <i>Hepatology</i> , 2017, 65, 749-750.	3.6	1
57	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	1.4	4
58	World Gastroenterology Organisation Global Guideline Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 691-703.	1.1	14
59	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. <i>Hepatology</i> , 2016, 63, 138-147.	3.6	253
60	Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). <i>Antiviral Research</i> , 2016, 132, 70-75.	1.9	18
61	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	1.8	84
62	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	1.8	358
63	An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B. <i>Liver International</i> , 2015, 35, 1824-1832.	1.9	17
64	Time to Make the Change from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis". <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 293-293.	0.8	9
65	Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. <i>Journal of Hepatology</i> , 2015, 63, 722-732.	1.8	97
66	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	1.8	398
67	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	1.8	138
68	Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). <i>Hepatology</i> , 2015, 61, 1512-1522.	3.6	145
69	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2071-2087.e16.	2.4	90
70	Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. <i>Hepatology</i> , 2015, 62, 87-100.	3.6	96
71	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
72	Immigration and viral hepatitis. <i>Journal of Hepatology</i> , 2015, 63, 515-522.	1.8	114

#	ARTICLE	IF	CITATIONS
73	Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy. <i>Antiviral Research</i> , 2015, 123, 86-92.	1.9	15
74	The impact of <sc>PNPLA</sc>3 (<rs>rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. <i>Liver International</i> , 2015, 35, 438-447.	1.9	29
75	Kupffer Cells Interact With Hepatitis B Surface Antigen In Vivo and In Vitro, Leading to Proinflammatory Cytokine Production and Natural Killer Cell Function. <i>Journal of Infectious Diseases</i> , 2015, 211, 1268-1278.	1.9	60
76	Experimental Hbsag/Anti-Hbs Complex Assay for Prediction of Hbeag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon and Adefovir. <i>Antiviral Therapy</i> , 2014, 19, 259-267.	0.6	11
77	Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. <i>Antiviral Research</i> , 2014, 111, 53-59.	1.9	163
78	Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. <i>Journal of Hepatology</i> , 2014, 60, 231-232.	1.8	3
79	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. <i>Journal of Hepatology</i> , 2014, 60, 1249-1258.	1.8	113
80	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	1.8	18
81	Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 517-524.	0.6	137
82	Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. <i>Digestive and Liver Disease</i> , 2014, 46, 720-725.	0.4	32
83	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196.	1.8	40
84	Role of T cell immunity in hepatitis C virus infections. <i>Current Opinion in Virology</i> , 2013, 3, 461-467.	2.6	28
85	Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: Is the glass half full or half empty?. <i>Hepatology</i> , 2013, 58, 1885-1887.	3.6	24
86	Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , 2013, 58, 898-903.	1.8	46
87	Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , 2013, 97, 312-317.	1.9	16
88	External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1201-1204.	2.4	218
89	Treatment of HCV Infection by Targeting MicroRNA. <i>New England Journal of Medicine</i> , 2013, 368, 1685-1694.	13.9	1,939
90	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. <i>Hepatology</i> , 2013, 57, 1962-1968.	3.6	237

#	ARTICLE	IF	CITATIONS
91	Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. <i>Carcinogenesis</i> , 2013, 34, 2330-2340.	1.3	50
92	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , 2013, 58, 872-880.	3.6	201
93	Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B. <i>Antiviral Therapy</i> , 2013, 19, 423-427.	0.6	1
94	Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon- α 2A and Adefovir. <i>Antiviral Therapy</i> , 2013, 18, 895-904.	0.6	70
95	Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon- α 2B: Relation to Response and HBV Genotype. <i>Antiviral Therapy</i> , 2012, 17, 9-17.	0.6	63
96	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α -2a. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1012-1019.	0.8	11
97	Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir. <i>Antiviral Therapy</i> , 2012, 17, 1605-1608.	0.6	15
98	Identification and treatment of chronic hepatitis B in Chinese migrants: Results of a project offering on-site testing in Rotterdam, The Netherlands. <i>Journal of Hepatology</i> , 2012, 57, 1171-1176.	1.8	37
99	Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study. <i>Journal of Hepatology</i> , 2012, 57, 1305-1311.	1.8	198
100	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. <i>Journal of Hepatology</i> , 2012, 56, 520-526.	1.8	114
101	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , 2012, 56, 1006-1011.	1.8	155
102	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	0.6	171
103	Immunology of hepatitis C virus infections. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 391-400.	1.0	21
104	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 67-75.	3.6	75
105	Hypercoagulability and Hypofibrinolysis and Risk of Deep Vein Thrombosis and Splanchnic Vein Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 485-493.	1.1	54
106	A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2011, 51, 175-178.	1.6	49
107	Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 209-218.	1.8	171
108	Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. <i>Journal of Hepatology</i> , 2011, 54, 449-454.	1.8	134

#	ARTICLE	IF	CITATIONS
109	The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued. <i>Journal of Hepatology</i> , 2011, 54, 395-396.	1.8	4
110	Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2011, 54, 908-914.	1.8	12
111	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	1.8	280
112	The response to TLR ligation of human CD16+CD14 ^{hi} monocytes is weakly modulated as a consequence of persistent infection with the hepatitis C virus. <i>Molecular Immunology</i> , 2011, 48, 1505-1511.	1.0	9
113	HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. <i>Journal of Medical Virology</i> , 2011, 83, 1917-1923.	2.5	3
114	Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. <i>Antiviral Therapy</i> , 2010, 15, 765-773.	0.6	4
115	Prediction of the response to peginterferon- α in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. <i>Journal of Medical Virology</i> , 2010, 82, 1135-1142.	2.5	39
116	A Randomized Trial of Peginterferon α -2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2010, 105, 1762-1769.	0.2	83
117	Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 139, 491-498.	0.6	180
118	Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 315-321.	1.8	132
119	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010, 52, 493-500.	1.8	103
120	New approaches in the management of chronic hepatitis B: role of tenofovir. <i>Infection and Drug Resistance</i> , 2009, 2, 13.	1.1	4
121	Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. <i>Journal of Hepatology</i> , 2009, 50, 674-683.	1.8	41
122	Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy. <i>Journal of Hepatology</i> , 2009, 51, 224-226.	1.8	4
123	Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study. <i>Journal of Hepatology</i> , 2009, 51, 696-706.	1.8	98
124	Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon- α . <i>Gastroenterology</i> , 2009, 137, 2002-2009.	0.6	349
125	Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1093-1108.	1.0	25
126	Immunology of hepatitis B and hepatitis C virus infections. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1049-1061.	1.0	46

#	ARTICLE	IF	CITATIONS
127	Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. <i>Clinical Immunology</i> , 2008, 129, 419-427.	1.4	50
128	Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α -2b. <i>Gastroenterology</i> , 2008, 135, 459-467.	0.6	373
129	TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostics Factors in 124 Patients. <i>Gastroenterology</i> , 2008, 135, 808-815.	0.6	319
130	Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis. <i>Annals of Internal Medicine</i> , 2007, 147, 677.	2.0	539
131	Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. <i>Hepatology</i> , 2007, 46, 699-705.	3.6	50
132	Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?. <i>Liver Transplantation</i> , 2007, 13, 867-874.	1.3	29
133	Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon- α Therapy for Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 1087-1096.	0.6	25
134	Modelling of Early Viral Kinetics and Pegylated Interferon- α 2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 1285-1294.	0.6	9
135	The effect of pegylated interferon- α on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. <i>Journal of Hepatology</i> , 2006, 44, 507-511.	1.8	24
136	Low incidence of retinopathy during peginterferon α -2b and lamivudine therapy for chronic hepatitis B. <i>Journal of Hepatology</i> , 2006, 45, 160-161.	1.8	4
137	Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. <i>Liver International</i> , 2006, 26, 399-405.	1.9	36
138	Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. <i>Hepatology</i> , 2006, 44, 53-61.	3.6	534
139	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. <i>Hepatology</i> , 2006, 44, 721-727.	3.6	63
140	Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype. <i>American Journal of Gastroenterology</i> , 2006, 101, 297-303.	0.2	249
141	Pathogenesis and Treatment of Budd-Chiari Syndrome Combined with Portal Vein Thrombosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 83-90.	0.2	102
142	Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine. <i>American Journal of Gastroenterology</i> , 2006, 101, 2523-2529.	0.2	27
143	Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs. <i>Hepatology</i> , 2005, 42, 1459-1459.	3.6	6
144	Pegylated Interferon- α 2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Annals of Internal Medicine</i> , 2005, 143, 391.	2.0	1

#	ARTICLE	IF	CITATIONS
145	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. <i>Lancet</i> , The, 2005, 365, 123-129.	6.3	1,105
146	Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2005, 43, 45-52.	1.8	42
147	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. <i>Hepatology</i> , 2004, 39, 500-508.	3.6	315
148	Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. <i>Hepatology</i> , 2004, 39, 804-810.	3.6	321
149	Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients. <i>Journal of Medical Virology</i> , 2004, 72, 215-222.	2.5	18
150	Budd-Chiari syndrome: a review by an expert panel. <i>Journal of Hepatology</i> , 2003, 38, 364-371.	1.8	446
151	Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. <i>Gastroenterology</i> , 2001, 121, 131-139.	0.6	264
152	The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2001, 35, 338-343.	1.8	92
153	Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. <i>Journal of Hepatology</i> , 2000, 33, 509-512.	1.8	36
154	Measurement of HBsAg to monitor hepatitis B viral replication in patients on α -interferon therapy. <i>Antiviral Research</i> , 1994, 23, 251-257.	1.9	51
155	Repeated courses of α -interferon for treatment of chronic hepatitis type B. <i>Journal of Hepatology</i> , 1993, 17, S47-S51.	1.8	28